Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Journal of Nutrition, Health and Aging

Volumn 16, Issue 6, 2012, Pages 557-561

  Gurevich, A ^a   Guller, V ^b   Berner, Y N ^c   Tal, S ^b  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atypical antipsychotics; BPSD; Conventional antipsychotics; Dementia; Elderly

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

ACUTE DYSTONIC REACTION; AKATHISIA; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOM OF DEMENTIA; BLURRED VISION; BREAST CANCER; CEREBROVASCULAR DISEASE; CONSTIPATION; DEEP VEIN THROMBOSIS; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYNDROME; HEART ARREST; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; OSTEOPOROSIS; PARKINSONISM; PRIORITY JOURNAL; PUPIL DISEASE; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; SWEATING; TARDIVE DYSKINESIA; URINE RETENTION; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; XEROSTOMIA;

EID: 85027952533     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0057-5     Document Type: Review

References (57)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005;19:1934-43.
2. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009;59:1-12.
3. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-63. (Pubitemid 20177819)
4. Jeste DV, Dolder CR, Nayak GV, Salzman C. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatry 2005;13:340-51. (Pubitemid 43048618)
5. Schneider LS, Dagerman K, Insel, PS. Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, Placebo-controlled trials. Am J Geriatric Psychiatry 2006;14:191-210.
6. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, With a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 2011;10:35-43.
7. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, Pharmacokinetics, And efficacy. Ann Pharmacother 1999;33:73-85. (Pubitemid 29056560)
8. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006;23:937-56. (Pubitemid 44936061)
9. Gardner D, Baldessarini R.J, Waraich P. Modern antipsychotic agents: A brief overview. Can Med Assoc J 2005;72:1703-11. (Pubitemid 40896865)
10. Carson S, McDonagh MS, Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia J Am Geriatr Soc 2006;54:354-61.
11. Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-1162. (Pubitemid 34044183)
12. De Deyn PP, Rabheru K, Rasmussen A, et aL. A randomized trial of risperidone, Placebo, And haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-55. (Pubitemid 29442108)
13. Brodaty H, Ames D, Snowden J, et aL. A randomized placebo controlled trial of risperidone for the treatment of aggression, Agitation, And psychosis in dementia. J Clin Psychiatry 2003;64:134-43. (Pubitemid 36268315)
14. Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002;(2):CD002852.
15. Maguire GA. Impact of antipsychotics on geriatric patients: efficacy, Dosing, And compliance. Prim Care Companion J Clin Psychiatry. 2000:2:165-72.
16. Fabbrini G, Barbanti P, Aurilia C. Tardive dyskinesias in the elderly. Int J Geriatr Psychiatry 2001;16:S19-S23. (Pubitemid 33741565)
17. Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62:15-8. (Pubitemid 32937573)
18. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006;21:589-98. (Pubitemid 43792739)
19. Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis and Treat 2006;2:235-40. (Pubitemid 44043618)
20. Katz I, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, Double blind trial. J Clin Psychiatry 1999; 60:107-15. (Pubitemid 29104387)
21. Bouman WP, Pinner G: Use of atypical antipsychotic drugs in old age psychiatry. Adv Psychiatr Treat 2002;8:49-58. (Pubitemid 34071595)
22. Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R. Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol Biol Sci Med Sci 2005;60:622-6. (Pubitemid 40847931)
23. Hien Ie TT, Cumming RG, Sanbroook PN. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005;53:1290-5. (Pubitemid 41602473)
24. Motsinger CD, Perron GA, Lacy TJ. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 2003;67:2335-40. (Pubitemid 36667084)
25. Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry 2004;16:75-8.
26. Avorn J, Monane M, Everitt DE, Beers MH, Fields D. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 1994;154:1113-7. (Pubitemid 24155210)
27. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, Implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37:193-220. (Pubitemid 36321747)
28. Holt RIG, Peveler RC, Byrne CD. Schizophrenia, The metabolic syndrome and diabetes. Diabet Med 2004;21:515-23. (Pubitemid 38746268)
29. Akhtar S, Kelly C, Gallagher A, Petrie Jr. Newer antipsychotic agents, Carbohydrate metabolism and cardiovascular risk. Brit J Diabetes Vasc Dis 2004;4:303-9. (Pubitemid 39462107)
30. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychotic-induced weight gain: bipolar disorders and leptin. J Clin Psychopharmacol 2003;23:323-7. (Pubitemid 36951172)
31. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62:15-26. (Pubitemid 34052253)
32. Sowell MO, Mukhopadhyay N, Cavazzoni P, et aL. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, Risperidone, Or placebo. J Clin Endocrinol Metab 2002;87:2918-23. (Pubitemid 34655364)
33. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72.
34. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:27-35.
35. Alberti KG, Zimmet P, Shaw J. The IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-62.
36. Lieberman JA. Metabolic changes associated with antipsychotic use. Prim Care Companion Clin Psychiatry 2004;6:8-13.
37. Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr News 2003;38:1.
38. Show 28: warning about hyperglycemia and atypical antipsychotic drugs webcast. Http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm? show=28. FDA Safety News. June, 2004.
39. Dalton SO, Johansen C, Poulsen AH, et aL. Cancer risk among users of neuroleptic medication: a population-based cohort study. Brit J Cancer 2006;95:934-9. (Pubitemid 44498111)
40. Wang PS, Walker AM, Tsuang MT, et aL. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002:59:1147-54. (Pubitemid 35424025)
41. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005;165:2677-82. (Pubitemid 41785068)
42. Love RC. Novel versus conventional antipsychotic drugs. Pharmacotherapy 1996;16:6-10.
43. Hagg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6. (Pubitemid 30172939)
44. Lieberman JA. Managing anticholinergic side effects. Prim Care J Clin Psychiatry 2004;6:20-3.
45. Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001;18:45-63.
46. Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. London, UK. Medicines and Healthcare Products Regulatory Agency, 2004.
47. Douglas IJ. Exposure to antipsychotics and risk of stroke: self controlled case series study. Brit Med J 2008;1227-32.
48. Sacchetti E, Trifiro G, Caputi A, et aL. Risk of stroke with typical and atypical antipsychotics: a retrospective cohort study including unexposed subject. J Psychopharmacol 2008; 22: 39-46.
49. Gill SS, Rochon PA, Herrmann N, et aL. Atypical antipsychotic drugs and risk of ischemic stroke: population based retrospective cohort study. BMJ, 2005 doi:10.1136/bmj.38330.470486.8F (Epub 2005 January 24). (Pubitemid 40314208)
50. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotics and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
51. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death-how should we manage the risk? N Engl J Med 2009;360;294-6.
52. Liperoti R, Gambassi G, Lapane KL, et aL. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest Arch Intern Med 2005;165:696-701. (Pubitemid 40393155)
53. FDA-US. Food and Drug Administration: 2009 Public Health Advisories: Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm053171.htm
54. Kales HC, Valenstein M, Kim HM, et aL. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164:1568-76. (Pubitemid 350069737)
55. Gill SS, Bronskill SE, Normand SL, et aL. Antipsychotic drug use and mortality in older adults with dementia. Ann Inter Med 2007;146:775-86. (Pubitemid 351650498)
56. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can Med Assoc J 2007;176:627-32. (Pubitemid 46426056)
57. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J 2011;183:E411-E419.